Cargando…

Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast

The grade of recurrent in situ and invasive carcinoma occurring after treatment of pure ductal carcinoma in situ (DCIS) has been compared with the grade of the original DCIS in 122 patients from four different centres (The Royal Marsden Hospitals, London and Sutton, 57 patients; Guy's Hospital,...

Descripción completa

Detalles Bibliográficos
Autores principales: Millis, R R, Pinder, S E, Ryder, K, Howitt, R, Lakhani, S R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409719/
https://www.ncbi.nlm.nih.gov/pubmed/15083182
http://dx.doi.org/10.1038/sj.bjc.6601704
_version_ 1782155842625208320
author Millis, R R
Pinder, S E
Ryder, K
Howitt, R
Lakhani, S R
author_facet Millis, R R
Pinder, S E
Ryder, K
Howitt, R
Lakhani, S R
author_sort Millis, R R
collection PubMed
description The grade of recurrent in situ and invasive carcinoma occurring after treatment of pure ductal carcinoma in situ (DCIS) has been compared with the grade of the original DCIS in 122 patients from four different centres (The Royal Marsden Hospitals, London and Sutton, 57 patients; Guy's Hospital, London, 19 patients; Nottingham City Hospital, 31 patients and The Royal Liverpool Hospital, 15 patients). The recurrent carcinoma was pure DCIS in 70 women (57%) and in 52 women (43%) invasive carcinoma was present, which was associated with an in situ element in 43. In all, 19 patients developed a second recurrence (pure DCIS in 11 and invasive with or without an in situ element in eight). The majority of invasive carcinomas followed high-grade DCIS. There was strong agreement between the grade of the original DCIS and that of the recurrent DCIS (κ=0.679), which was the same in 95 of 113 patients (84%). The grade of the original DCIS showed only fair agreement with the grade of recurrent invasive carcinoma (κ=0.241), although agreement was stronger with the pleomorphism score of the recurrent carcinoma (κ=0.396). There was moderate agreement, in recurrent invasive lesions, between the grade of the DCIS and that of the associated invasive element (κ=0.515). Other features that showed moderate or strong agreement between the original and recurrent DCIS were necrosis and periductal inflammation. The similarity between the histological findings of the original and subsequent DCIS is consistent with the concept that recurrent lesions represent regrowth of residual carcinoma. In addition, although agreement between the grade of the original DCIS and that of any subsequent invasive carcinoma was only fair, there is no suggestion that low-grade DCIS lesions progress to higher grade lesions or to the development of higher grade invasive carcinoma. This is in agreement with immunohistochemical and molecular data indicating that low-grade and high-grade mammary carcinomas are quite different lesions.
format Text
id pubmed-2409719
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24097192009-09-10 Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast Millis, R R Pinder, S E Ryder, K Howitt, R Lakhani, S R Br J Cancer Molecular and Cellular Pathology The grade of recurrent in situ and invasive carcinoma occurring after treatment of pure ductal carcinoma in situ (DCIS) has been compared with the grade of the original DCIS in 122 patients from four different centres (The Royal Marsden Hospitals, London and Sutton, 57 patients; Guy's Hospital, London, 19 patients; Nottingham City Hospital, 31 patients and The Royal Liverpool Hospital, 15 patients). The recurrent carcinoma was pure DCIS in 70 women (57%) and in 52 women (43%) invasive carcinoma was present, which was associated with an in situ element in 43. In all, 19 patients developed a second recurrence (pure DCIS in 11 and invasive with or without an in situ element in eight). The majority of invasive carcinomas followed high-grade DCIS. There was strong agreement between the grade of the original DCIS and that of the recurrent DCIS (κ=0.679), which was the same in 95 of 113 patients (84%). The grade of the original DCIS showed only fair agreement with the grade of recurrent invasive carcinoma (κ=0.241), although agreement was stronger with the pleomorphism score of the recurrent carcinoma (κ=0.396). There was moderate agreement, in recurrent invasive lesions, between the grade of the DCIS and that of the associated invasive element (κ=0.515). Other features that showed moderate or strong agreement between the original and recurrent DCIS were necrosis and periductal inflammation. The similarity between the histological findings of the original and subsequent DCIS is consistent with the concept that recurrent lesions represent regrowth of residual carcinoma. In addition, although agreement between the grade of the original DCIS and that of any subsequent invasive carcinoma was only fair, there is no suggestion that low-grade DCIS lesions progress to higher grade lesions or to the development of higher grade invasive carcinoma. This is in agreement with immunohistochemical and molecular data indicating that low-grade and high-grade mammary carcinomas are quite different lesions. Nature Publishing Group 2004-04-19 2004-03-30 /pmc/articles/PMC2409719/ /pubmed/15083182 http://dx.doi.org/10.1038/sj.bjc.6601704 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Millis, R R
Pinder, S E
Ryder, K
Howitt, R
Lakhani, S R
Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
title Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
title_full Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
title_fullStr Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
title_full_unstemmed Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
title_short Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
title_sort grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409719/
https://www.ncbi.nlm.nih.gov/pubmed/15083182
http://dx.doi.org/10.1038/sj.bjc.6601704
work_keys_str_mv AT millisrr gradeofrecurrentinsituandinvasivecarcinomafollowingtreatmentofpureductalcarcinomainsituofthebreast
AT pinderse gradeofrecurrentinsituandinvasivecarcinomafollowingtreatmentofpureductalcarcinomainsituofthebreast
AT ryderk gradeofrecurrentinsituandinvasivecarcinomafollowingtreatmentofpureductalcarcinomainsituofthebreast
AT howittr gradeofrecurrentinsituandinvasivecarcinomafollowingtreatmentofpureductalcarcinomainsituofthebreast
AT lakhanisr gradeofrecurrentinsituandinvasivecarcinomafollowingtreatmentofpureductalcarcinomainsituofthebreast